A Study to Investigate the Effects of PF00610335 on the QT/QTC Interval in Healthy Volunteers

NCT01107054 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

48

Enrollment

INDUSTRY

Sponsor class

Conditions

Pulmonary Disease
Lung Disease
Moxifloxacin

Interventions

DRUG: PF-00610355
DRUG: PF-00610355
DRUG: moxifloxacin
DRUG: placebo

Sponsor

Pfizer